Swiss National Bank Has $467,000 Position in TransEnterix, Inc. (NYSEAMERICAN:TRXC)

Swiss National Bank boosted its stake in shares of TransEnterix, Inc. (NYSEAMERICAN:TRXC) by 8.9% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 343,300 shares of the medical instruments supplier’s stock after buying an additional 28,200 shares during the quarter. Swiss National Bank’s holdings in TransEnterix were worth $467,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in TRXC. Sheets Smith Wealth Management lifted its holdings in TransEnterix by 100.0% during the 1st quarter. Sheets Smith Wealth Management now owns 20,000 shares of the medical instruments supplier’s stock worth $48,000 after buying an additional 10,000 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in TransEnterix by 3,781.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 35,162 shares of the medical instruments supplier’s stock worth $84,000 after buying an additional 34,256 shares during the period. Edmond DE Rothschild Holding S.A. acquired a new position in TransEnterix during the 1st quarter worth about $136,000. SG Americas Securities LLC lifted its holdings in TransEnterix by 921.4% during the 2nd quarter. SG Americas Securities LLC now owns 212,259 shares of the medical instruments supplier’s stock worth $289,000 after buying an additional 191,477 shares during the period. Finally, Bank of America Corp DE lifted its holdings in TransEnterix by 45.9% during the 4th quarter. Bank of America Corp DE now owns 129,949 shares of the medical instruments supplier’s stock worth $294,000 after buying an additional 40,852 shares during the period.

Several research analysts have commented on the company. Zacks Investment Research downgraded TransEnterix from a “hold” rating to a “sell” rating in a report on Saturday, July 13th. Royal Bank of Canada downgraded TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price objective on the stock. in a research note on Thursday, August 8th. Finally, Piper Jaffray Companies started coverage on TransEnterix in a research note on Wednesday, May 22nd. They issued a “neutral” rating and a $1.60 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $2.62.

Shares of NYSEAMERICAN:TRXC traded up $0.02 during midday trading on Friday, reaching $0.76. The company’s stock had a trading volume of 1,958,288 shares, compared to its average volume of 2,616,079. TransEnterix, Inc. has a fifty-two week low of $0.62 and a fifty-two week high of $6.98.

TransEnterix (NYSEAMERICAN:TRXC) last announced its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $3.64 million during the quarter, compared to the consensus estimate of $5.13 million.

TransEnterix Profile

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Further Reading: Purposes and Functions of the Federal Reserve

Want to see what other hedge funds are holding TRXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransEnterix, Inc. (NYSEAMERICAN:TRXC).

Institutional Ownership by Quarter for TransEnterix (NYSEAMERICAN:TRXC)

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.